Skip to main content

Advertisement

SpringerLink
Log in

Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

It is unclear whether vitamin K antagonists affect stroke severity and outcome in patients with atrial fibrillation (AF). We aimed to evaluate this association. We prospectively studied 539 consecutive patients admitted with acute ischemic stroke (41.2 % males, age 78.9 ± 6.6 years). The severity of stroke was assessed at admission with the National Institutes of Health Stroke Scale (NIHSS). The outcome was assessed with dependency rates at discharge (modified Rankin scale 2–5) and with in-hospital mortality. 177 patients had a history of AF. The median NIHSS at admission did not differ between patients on acenocoumarol with INR 2.0–3.0, on acenocoumarol with INR < 2.0, on single antiplatelet treatment, on dual antiplatelet treatment, or on no treatment [4 (range 0–26), 13 (0–39), 8 (0–33), 3 (2–23) and 7 (0–33), respectively; p = 0.433]. Dependency rates were lower in patients on acenocoumarol with INR 2.0–3.0 or on dual antiplatelet treatment than in those on acenocoumarol with INR < 2.0, single antiplatelet treatment, or no treatment (20.0, 22.2, 61.5, 58.7 and 68.0 %, respectively; p = 0.024). Independent predictors of dependency were age, NIHSS at admission and history of ischemic stroke. In-hospital mortality did not differ between patients on acenocoumarol with INR 2.0–3.0, on acenocoumarol with INR < 2.0, on single antiplatelet treatment, on dual antiplatelet treatment, or on no treatment (7.7, 18.2, 16.1, 16.7 and 22.2 %, respectively; p = 0.822). In conclusion, optimally anticoagulated patients with AF have more favorable functional outcome after stroke and a trend for less severe stroke whereas patients with subtherapeutic anticoagulation have similar stroke severity and outcome with those on no treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370–2375

    Article  CAS  PubMed  Google Scholar 

  2. Heeringa J, van der Kuip DA, Hofman A et al (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27:949–953

    Article  PubMed  Google Scholar 

  3. Magnani JW, Rienstra M, Lin H et al (2011) Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation 124:1982–1993

    Article  PubMed Central  PubMed  Google Scholar 

  4. Hannon N, Sheehan O, Kelly L, Marnane M et al (2010) Stroke associated with atrial fibrillation-incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis 29:43–49

    Article  PubMed  Google Scholar 

  5. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988

    Article  CAS  PubMed  Google Scholar 

  6. McGrath ER, Kapral MK, Fang J, Investigators of the Ontario Stroke Registry et al (2013) Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology 81:825–832

    Article  PubMed  Google Scholar 

  7. Lin HJ, Wolf PA, Kelly-Hayes M et al (1996) Stroke severity in atrial fibrillation: the Framingham Study. Stroke 27:1760–1764

    Article  CAS  PubMed  Google Scholar 

  8. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867

    Article  PubMed  Google Scholar 

  9. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R et al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903–1912

    Article  Google Scholar 

  10. Baczek VL, Chen WT, Kluger J et al (2012) Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract 13:5

    Article  PubMed Central  PubMed  Google Scholar 

  11. Kirley K, Qato DM, Kornfield R et al (2012) National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 5:615–621

    Article  PubMed Central  PubMed  Google Scholar 

  12. Baker WL, Cios DA, Sander SD et al (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15:244–252

    PubMed  Google Scholar 

  13. Hylek EM, Skates SJ, Sheehan MA et al (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540–546

    Article  CAS  PubMed  Google Scholar 

  14. Haeusler KG, Konieczny M, Endres M et al (2012) Impact of anticoagulation before stroke on stroke severity and long-term survival. Int J Stroke 7:544–550

    Article  PubMed  Google Scholar 

  15. Johnsen SP, Svendsen ML, Hansen ML et al (2014) Preadmission oral anticoagulant treatment and clinical outcome among patients hospitalized with acute stroke and atrial fibrillation: a nationwide study. Stroke 45:168–175

    Article  CAS  PubMed  Google Scholar 

  16. Schwammenthal Y, Bornstein N, Schwammenthal E et al (2010) Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival. Am J Cardiol 105:411–416

    Article  PubMed  Google Scholar 

  17. O’Donnell M, Oczkowski W, Fang J et al (2006) Investigators of the registry of the Canadian stroke network: preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol 5:749–754

    Article  PubMed  Google Scholar 

  18. Hannon N, Callaly E, Moore A et al (2011) Improved late survival and disability after stroke with therapeutic anticoagulation for atrial fibrillation: a population study. Stroke 42:2503–2508

    Article  PubMed  Google Scholar 

  19. Indredavik B, Rohweder G, Lydersen S (2005) Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J Intern Med 258:133–144

    Article  CAS  PubMed  Google Scholar 

  20. Hylek EM, Go AS, Chang Y et al (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019–1026

    Article  CAS  PubMed  Google Scholar 

  21. Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee and Investigators et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  CAS  PubMed  Google Scholar 

  22. Patel MR, Mahaffey KW, Garg J, ROCKET AF Investigators et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891

    Article  CAS  PubMed  Google Scholar 

  23. Granger CB, Alexander JH, McMurray JJ, ARISTOTLE Committees and Investigators et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992

    Article  CAS  PubMed  Google Scholar 

  24. Xu Y, Holbrook AM, Simpson CS et al (2013) Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open 1:E115–E119

    Article  PubMed Central  PubMed  Google Scholar 

  25. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502

    CAS  PubMed  Google Scholar 

  26. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470

    Article  CAS  PubMed  Google Scholar 

  27. Gladstone DJ, Bui E, Fang J et al (2009) Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40:235–240

    Article  CAS  PubMed  Google Scholar 

  28. Camm AJ, Lip GY, De Caterina R, ESC Committee for Practice Guidelines (CPG) et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European heart rhythm association. Eur Heart J 33:2719–2747

    Article  PubMed  Google Scholar 

  29. Fang MC, Go AS, Chang Y et al (2012) Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 43:1795–1799

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Investigators ACTIVE, Connolly SJ, Pogue J, Hart RG et al (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360:2066–2078

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi Street, 54636, Thessaloníki, Greece

    Konstantinos Tziomalos, Vasilios Giampatzis, Stella D. Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Vasiliki Dourliou, Areti Sofogianni, Christos Savopoulos & Apostolos I. Hatzitolios

Authors
  1. Konstantinos Tziomalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vasilios Giampatzis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stella D. Bouziana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marianna Spanou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stavroula Kostaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Papadopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vasiliki Dourliou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Areti Sofogianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christos Savopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Apostolos I. Hatzitolios
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos Tziomalos.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tziomalos, K., Giampatzis, V., Bouziana, S.D. et al. Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation. J Thromb Thrombolysis 41, 336–342 (2016). https://doi.org/10.1007/s11239-015-1262-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-015-1262-y

Keywords

Search

Navigation